Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06552611 · ClinicalTrials.gov registry record · Phase 1
Non-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis
A Phase 1 study of Multiple Sclerosis, sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT06552611 is a Phase 1 study of Multiple Sclerosis that is actively recruiting participants, run by University of Washington. The registered enrollment target is 4 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06552611, a Phase 1 study of Multiple Sclerosis, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
Current disease-modifying therapies for multiple sclerosis (MS) aim to prevent the development of new lesions; unfortunately, no current FDA-approved therapies promote central nervous system (CNS) repair mechanisms. Thus, strategies to promote functional recovery from lesion-related deficits in adults with MS remain an unmet need. This is a pilot study designed to test the feasibility, safety and preliminary efficacy of non-invasive (transcutaneous, applied by surface electrodes over the skin) electrical spinal cord stimulation combined with occupational therapy for restoring upper extremity sensorimotor function in adults with multiple sclerosis. Participants with multiple sclerosis and impaired upper extremity function will complete two separate 6-week intervention sessions: 6 weeks of occupational therapy combined with transcutaneous spinal cord stimulation and 6 weeks of occupational therapy alone. The order of these interventions will be randomized, and each intervention will be separated by a 6-week washout period. The investigators hypothesize that: 1. transcutaneous spinal cord stimulation combined with therapy will be feasible and acceptable by participants 2. transcutaneous spinal cord stimulation combined with therapy will lead to improvements in upper extremity function compared to occupational therapy alone 3. transcutaneous spinal cord stimulation combined with therapy will lead to improvements in symptoms related to quality of life (pain, spasticity, and bladder symptoms) compared to occupational therapy alone
Conditions Studied
Interventions
- COMBINATION_PRODUCT Transcutaneous electrical spinal cord stimulation + therapy
- OTHER Occupational Therapy
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06552611
The ClinicalTrials.gov registry entry for NCT06552611 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (99% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Transcutaneous electrical spinal cord stimulation + therapy is the first listed.
NCT06552611 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT06552611 about?
NCT06552611 is a clinical study titled "Non-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis". Current disease-modifying therapies for multiple sclerosis (MS) aim to prevent the development of new lesions; unfortunately, no current FDA-approved therapies promote central nervous system (CNS) repair mechanisms. Thus, strategies to promote functional recovery from lesion-related deficits in adul...
What is the current status of trial NCT06552611?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2024-08-08. Estimated completion is 2025-07-01.
What conditions does trial NCT06552611 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT06552611?
The interventions under investigation include: Transcutaneous electrical spinal cord stimulation + therapy (COMBINATION_PRODUCT), Occupational Therapy (OTHER).
Who is sponsoring clinical trial NCT06552611?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06552611 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
RECRUITING · Phase 1
-
Molecular Imaging of NET Using [C-11]MRB-PET in MS
RECRUITING · Phase 1
-
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.